AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

The theory behind leucovorin's use for autism postulates that some children have a blockage in the transport of folic acid into the brain that potentially contributes to neurological symptoms.

A new study found that children whose mothers took an essential vitamin early in pregnancy had significantly higher verbal ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -SOUTH SAN FRANCISCO, Calif., March 15, ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

When their son, Mason, now 5, was diagnosed with nonverbal autism at two-and-a-half years old, the Connor family was determined to find something to help him speak. After multiple failed treatments, ...

For example, when we inactivate (knock out) the folate receptor (Forl1) gene-its protein product which is a receptor molecule that brings vitamin B9 (folic acid) into cells is eliminated, and the ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

Safety was consistent across dosing groups, with no new safety signals observed and neutropenia well-managed. The majority of patients across both dose cohorts received prior bevacizumab. The ...

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE� (mirvetuximab soravtansine-gynx) in women with folate ...